{"id":"NCT04571944","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)","officialTitle":"A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of MK-4305 (Suvorexant) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-22","primaryCompletion":"2022-12-23","completion":"2022-12-23","firstPosted":"2020-10-01","resultsPosted":"2024-05-20","lastUpdate":"2024-11-25"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Delirium"],"interventions":[{"type":"DRUG","name":"Suvorexant","otherNames":["MK-4305"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Suvorexant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this study is to evaluate the efficacy and safety of suvorexant (MK-4305) for reducing the incidence of delirium in Japanese participants who are at high risk of delirium. The primary hypothesis is that suvorexant reduces the proportion of participants with delirium compared with placebo as assessed by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria.","primaryOutcome":{"measure":"Percentage of Participants With Delirium as Assessed by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Criteria","timeFrame":"Up to ~8 days","effectByArm":[{"arm":"Suvorexant","deltaMin":16.8,"sd":null},{"arm":"Placebo","deltaMin":26.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.129"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":50,"countries":["Japan"]},"refs":{"pmids":["39150711"],"seeAlso":["http://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":101},"commonTop":["Delirium","Constipation","Insomnia","Vomiting","Nausea"]}}